Atiqah Aziz is currently a Research Officer at Tissue Engineering Unit (TEG), National Orthopaedic Centre of Excellence for Research & Learning (NOCERAL), Department of Orthopaedics Surgery, Faculty of Medicine in Kuala Lumpur. She earned her Bachelor of Science in Biology at the University of Science Malaysia (USM) in Penang, in 2014, and completed her Master's Degree in Applied Biology at the University of Technology MARA (UiTM) in 2016. Currently, she is doing her Ph.D. In Applied Chemistry at the University of Malaya. She started her service with UM in 2008. Early in her career, she served at Shidmadzu-Centre for Xenobiotics Studies (SUCXeS) at the Department of Pharmacology, Faculty of Medicine for 6 years and she continues her service in the Surgical Simulation Lab at the Department of Otorhinolaryngology, Faculty of Medicine later in the year 2015. After completing her Master degree, Atiqah accepted a position as a Research Officer at UM Halal Research Centre (UMHRC) under the TNC (Research & Innovation), where she worked for 4 years. Atiqah has received several awards/scholarships, including the Universiti Malaya Scholarship throughout her study and a recipient of Swansea University Fulton Fellowship awarded by The Association 0f Commonwealth Universities (ACU), London, United Kingdom.Recently, she has been appointed as a Study Director under the Toxicology Testing Unit (TTU) for In-vitro testing in Medical devices and involve establishing the Good Laboratory Practice (GLP) in NOCERAL. She has also been appointed as a person who is charged to operate the Xtreme 3D quantitative computerized tomography (QCT) system. The device is used to measure the bone density and to quantify the 3D microarchitecture of the bone at the human or animal tibia and fibula for research activity and as part of services provided by the NOCERAL for external users including patients from UM Medical Centre (UMMC). As a researcher that interested in degenerative diseases, such as Osteoarthritis (OA), she would like to explore new biological therapy with “value-added methods” thereby moving closer to the treatment of OA since the treatment of OA has been quite limited. Hence, her research interest involves gene therapy, CRISPR technology, molecular and cancer biology.